Play all audios:
Access through your institution Buy or subscribe “Some of it is simply a maturation of the [biotech] industry,” says AUTM president-elect Patricia Harsche, of Fox Chase Cancer Center in
Philadelphia. “Many of the licenses that were entered into eight to ten years ago are now products.” Several one-time events, however, have inflated the total figure. The biggest—$200
million—was the University of California's settlement of two patent infringement lawsuits against biotech company Genentech for human growth hormone. But even without that settlement,
license income across the board for these institutions grew 23% with most of the money coming in the form of product royalties. This is a preview of subscription content, access via your
institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this
article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in
* Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Ann Arbor Ken Garber Authors * Ken Garber View author
publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Garber, K. Tech transfer pays
off. _Nat Med_ 8, 312 (2002). https://doi.org/10.1038/nm0402-312 Download citation * Issue Date: 01 April 2002 * DOI: https://doi.org/10.1038/nm0402-312 SHARE THIS ARTICLE Anyone you share
the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer
Nature SharedIt content-sharing initiative